Related Experiment Videos
Menorest: a clinical overview
1Menopause Centre, Royal Hospital for Women, Paddington, New South Wales, Australia.
Summary
Menorest, a 17 beta-estradiol patch, effectively manages menopause symptoms like hot flashes and vaginal dryness. It showed comparable efficacy to oral equine estrogens and another patch, with a potentially better side effect profile.
Area of Science:
- Endocrinology
- Gynecology
- Pharmacology
Background:
- Menopause is characterized by vasovagal and urinogenital symptoms.
- Hormone therapy is a common treatment for menopausal symptoms.
Purpose of the Study:
- To compare the efficacy and tolerability of Menorest (17 beta-estradiol patch) with oral equine estrogens and a reservoir estradiol patch.
Main Methods:
- A study comparing Menorest 50 mcg/day to Premarin 0.625 mg/day and Estraderm 50 mcg/day.
- Assessment of vasovagal and urinogenital symptom control.
- Monitoring of blood pressure and lipid profiles.
- Evaluation of treatment-related side effects.
Main Results:
- Menorest demonstrated equivalent efficacy to Premarin and Estraderm in alleviating menopausal symptoms.
- No significant changes in blood pressure or lipid profiles were observed with any treatment.
- Menorest exhibited a favorable tolerability profile, with fewer local side effects (erythema, itching) compared to Estraderm.
Conclusions:
- Menorest is an effective and well-tolerated option for managing menopausal symptoms.
- It offers comparable efficacy to existing therapies with potentially improved local tolerability.